Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 13

1.

Diabetes mellitus as a compelling indication for use of renin angiotensin system blockers: systematic review and meta-analysis of randomized trials.

Bangalore S, Fakheri R, Toklu B, Messerli FH.

BMJ. 2016 Feb 11;352:i438. doi: 10.1136/bmj.i438. Review. Erratum in: BMJ. 2016;352:i1525.

2.

Comparison of Azelnidipine and Trichlormethiazide in Japanese Type 2 Diabetic Patients with Hypertension: The COAT Randomized Controlled Trial.

Takihata M, Nakamura A, Kondo Y, Kawasaki S, Kimura M, Terauchi Y.

PLoS One. 2015 May 4;10(5):e0125519. doi: 10.1371/journal.pone.0125519. eCollection 2015 May 4.

3.

Systolic hypertension: an increasing clinical challenge in Asia.

Park JB, Kario K, Wang JG.

Hypertens Res. 2015 Apr;38(4):227-36. doi: 10.1038/hr.2014.169. Epub 2014 Dec 11. Review.

4.

RAAS inhibition and mortality in hypertension.

Ferrari R.

Glob Cardiol Sci Pract. 2013 Nov 1;2013(3):269-78. doi: 10.5339/gcsp.2013.34. eCollection 2013 Nov 1. Review.

6.

Blood pressure lowering and major cardiovascular events in people with and without chronic kidney disease: meta-analysis of randomised controlled trials.

Blood Pressure Lowering Treatment Trialists' Collaboration., Ninomiya T, Perkovic V, Turnbull F, Neal B, Barzi F, Cass A, Baigent C, Chalmers J, Li N, Woodward M, MacMahon S.

BMJ. 2013 Oct 3;347:f5680. doi: 10.1136/bmj.f5680. Review.

7.

Angiotensin-converting enzyme inhibitors reduce mortality in hypertension: a meta-analysis of randomized clinical trials of renin-angiotensin-aldosterone system inhibitors involving 158,998 patients.

van Vark LC, Bertrand M, Akkerhuis KM, Brugts JJ, Fox K, Mourad JJ, Boersma E.

Eur Heart J. 2012 Aug;33(16):2088-97. doi: 10.1093/eurheartj/ehs075. Epub 2012 Apr 17. Review.

8.

New Generation Calcium Channel Blockers in Hypertensive Treatment.

Ozawa Y, Hayashi K, Kobori H.

Curr Hypertens Rev. 2006 May 1;2(2):103-111.

9.
10.
11.

Reporting on sex-based analysis in clinical trials of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker efficacy.

Rabi DM, Khan N, Vallee M, Hladunewich MA, Tobe SW, Pilote L.

Can J Cardiol. 2008 Jun;24(6):491-6. Review.

12.
13.

Methods underpinning national clinical guidelines for hypertension: describing the evidence shortfall.

Campbell F, Dickinson HO, Cook JV, Beyer FR, Eccles M, Mason JM.

BMC Health Serv Res. 2006 Apr 5;6:47.

Supplemental Content

Support Center